Share Your Listing on Social Media to Increase Visibility

Report Abuse

0 0 Reviews

CAR-T Cell Therapy market Professional Survey Report by 2035

As the six approved CAR-T cell therapies, including Breyanzi®, Abecma™ and CARVYKTI™ are poised to achieve blockbuster status, along with a promising development pipeline, the field of CAR-T cell therapies has gained significant traction


Roots Analysis is pleased to announce the publication of its recent study, titled, “Global CAR T Cell Therapy Market (4th Edition), 2022-2035.”


The study features an in-depth analysis of key drivers and trends related to this domain. Amongst other elements, the report includes:

  • A detailed assessment of the current market landscape of CAR-T-cell therapies.
  • An analysis of key insights derived from the study featuring a competitive analysis, highlighting the popular target antigens related to hematological malignancies and solid tumors.
  • A detailed analysis of completed, ongoing and planned clinical studies related to CAR-T cell therapies.
  • An insightful analysis highlighting the key opinion leaders (KOLs) in this domain featuring an analysis of the various principal investigators of clinical trials related to CAR-T cell therapy.
  • Elaborate profiles of marketed and mid- to late-stage clinical products (phase I/II or above).
  • An analysis of various type of partnership that have been inked between several stakeholders in the domain of CAR-T-cell therapies.
  • An analysis of the investments that have been made into companies that have proprietary CAR-T cell-based products / technologies.
  • An in-depth analysis of patents related to CAR-T cell therapies, filed / granted till 2022.
  • A case study on manufacturing cell therapy products, highlighting the key challenges, and a detailed list of contract service providers and in-house manufacturers involved in this space.
  • An elaborate discussion on various factors that form the basis for the pricing of cell-based therapies.
  • A review of the key promotional strategies being adopted by the developers of the approved CAR-T cell therapies.
  • Elaborate profiles of the several leading players in the domain of CAR T cell therapies.


A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below):

  • Target Indication(s)
  • Non-Hodgkin’s Lymphoma
  • Multiple Myeloma
  • Acute Lymphoblastic Leukemia
  • Chronic Lymphocytic Leukemia
  • Hodgkin’s Lymphoma
  • Acute Myeloid Leukemia
  • Ovarian Cancer
  • Generalized Myasthenia Gravis (MG)
  • Renal Cell Carcinoma


  • Target Antigen
  • CD19
  • BCMA
  • CD19/22
  • Others


  • Key Geographical Regions
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and North Africa
  • Rest of the World


The research includes profiles of key players (listed below); each profile features a brief overview of the company, details related to its financial information (if available), details about CAR-T-cell based product(s), such as information on type of therapy and current development status, information on technology portfolio (if available), recent developments related to CAR-T cell immunotherapies and manufacturing capabilities of the players.


  • Autolus
  • bluebird Bio
  • Bristol Myers Squibb
  • Carsgen Therapeutics
  • Cellectis
  • Cellular Biomedicine Group
  • Gilead Sciences
  • Innovative Cellular Therapeutics
  • Kuur Therapeutics
  • Noile-Immune Biotech
  • Novartis
  • Shanghai GeneChem
  • Sinobioway Cell Therapy
  • Takara Bio
  • Wellington Zhaotai Therapies


Get more details on the CAR-T Cell Therapy Market report


You may also be interested in the following titles:

Bispecific Antibodies Market

Novel Cell Cytometers: Need of the Hour

Non-viral Drug Delivery Systems Market

Roots Analysis Consulting - the preferred research partner for global firms


About Roots Analysis

Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.



Ben Johnson

+1 (415) 800 3415




Author Info


Member since 11 months ago
View Profile

Contact Listings Owner Form

CAR-T Cell Therapy market Professional Survey Report by 2035 0 reviews

Login to Write Your Review

There are no reviews yet.